Background:Non-epithelial ovarian tumors, including germ cell tumors (GCTs) and sex cord–stromal tumors (SCSTs), are associated with favorable survival but potential long-term treatment sequelae. Previous results from the French TMRG/GINECO VIVROVAIRE study showed quality-of-life (QoL) impairments. This analysis further explored long-term outcomes by tumor subtype.Methods:Cancer-free GCT and SCST survivors (≥2 years post-treatment) were recruited through the French TMRG network and matched to healthy women (HW) by age and education. Participants completed questionnaires assessing QoL (FACT-G/FACT-O), fatigue (MFI), neurotoxicity (FACT/GOG-NTX), cognition (FACT-COG), psychological distress (HADS), insomnia (ISI), physical activity (IPAQ), and sexuality. Clinically meaningful differences were defined as ≥5%.Results:All of the 144 patients (99 GCT, 45 SCST) received surgery (fertility-sparing: 81% GCT, 69% SCST) and platinum-based chemotherapy. Median follow-up was 5.7 years. Matching 2:1 was performed with 284HW. Compared with HW, SCST survivors reported higher fatigue (MFI 52.0 vs 42.5, p=0.03) and severe neuropathy (36% vs 7%, p<0.001). Compared with HW, GCT survivors reported more cognitive complaints (37% vs 20%, p=0.002) and practiced less executive and intellectual professions (19% vs 36%, p =0.031). Premature menopause was more frequent than HW in both groups (GCT: 27% vs 6%, p<0.001; SCST: 73% vs 44%, p=0.004). Sexual QoL was deteriorated among GCT patients (reduced sexual interest: 29% vs 12%, p<0.001). Levels of psychological distress, insomnia and physical activity were similar across groups. Conclusions:Long-term sequelae differ by subtype: SCST survivors experience fatigue and neuropathy, whereas GCT survivors are affected by sexual dysfunction, and cognitive complaints with potential socio-professional implications.